Neurocrine Biosciences (NBIX) Amortization of Deferred Charges: 2017-2021
Historic Amortization of Deferred Charges for Neurocrine Biosciences (NBIX) over the last 5 years, with Dec 2021 value amounting to $300,000.
- Neurocrine Biosciences' Amortization of Deferred Charges fell 25.00% to $300,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $1.1 million, marking a year-over-year decrease of 21.43%. This contributed to the annual value of $700,000 for FY2023, which is 41.67% down from last year.
- Per Neurocrine Biosciences' latest filing, its Amortization of Deferred Charges stood at $300,000 for Q4 2021, which was up 50.00% from $200,000 recorded in Q3 2021.
- Neurocrine Biosciences' Amortization of Deferred Charges' 5-year high stood at $400,000 during Q2 2019, with a 5-year trough of $200,000 in Q3 2021.
- In the last 3 years, Neurocrine Biosciences' Amortization of Deferred Charges had a median value of $300,000 in 2021 and averaged $325,000.
- Its Amortization of Deferred Charges has fluctuated over the past 5 years, first skyrocketed by 58.94% in 2018, then slumped by 33.33% in 2021.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Amortization of Deferred Charges stood at $322,000 in 2017, then decreased by 3.42% to $311,000 in 2018, then rose by 28.62% to $400,000 in 2019, then remained steady at $400,000 in 2020, then declined by 25.00% to $300,000 in 2021.
- Its Amortization of Deferred Charges was $300,000 in Q4 2021, compared to $200,000 in Q3 2021 and $300,000 in Q2 2021.